TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia

American Journal of Hematology

Volumn 91, Issue 4, 2016, Pages 400-405

  Ghobrial, Irene M ^a   Siegel, David S ^b   Vij, Ravi ^c   Berdeja, Jesus G ^d   Richardson, Paul G ^a   Neuwirth, Rachel ^e   Patel, Chirag G ^e   Zohren, Fabian ^e   Wolf, Jeffrey L ^f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e MILLENNIUM PHARMACEUTICALS INC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CREATININE; TAK 228; UNCLASSIFIED DRUG; BENZOXAZOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SAPANISERTIB; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ACCUMULATION INDEX; ADULT; AGED; ANEMIA; APHTHOUS STOMATITIS; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL STUDY; CONSTIPATION; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; ERYTHEMA; FATIGUE; FEMALE; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOXIA; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEUTROPENIA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA; VISUAL ACUITY; VOMITING; WALDENSTROEM MACROGLOBULINEMIA; ANTAGONISTS AND INHIBITORS; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; DRUG MONITORING; LYMPHOMA, NON-HODGKIN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; RECURRENT DISEASE; RETREATMENT; TREATMENT OUTCOME; VERY ELDERLY; WALDENSTROM MACROGLOBULINEMIA;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZOXAZOLES; DRUG MONITORING; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIPROTEIN COMPLEXES; NEOPLASM GRADING; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECURRENCE; RETREATMENT; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 84961259098     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24300     Document Type: Article

References (47)

1. Zoncu R, Efeyan A, Sabatini DM. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
2. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011;23:744-755.
3. Sabatini DM. mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 2006;6:729-734.
4. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-345.
5. Benjamin D, Colombi M, Moroni C, et al. Rapamycin passes the torch: A new generation of mTOR inhibitors. Nat Rev Drug Discov 2011;10:868-880.
6. Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009;137:873-886.
7. Shi Y, Yan H, Frost P, et al. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005;4:1533-1540.
8. Vu C, Fruman DA. Target of rapamycin signaling in leukemia and lymphoma. Clin Cancer Res 2010;16:5374-5380.
9. Younes A, Samad N. Utility of mTOR inhibition in hematologic malignancies. Oncologist 2011;16:730-741.
10. Hsieh AC, Liu Y, Edlind MP, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012;485:55-61.
11. Westin JR. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk 2014;14:335-342.
12. Maiso P, Liu Y, Morgan B, et al. Defining the role of TORC1/2 in multiple myeloma. Blood 2011;118:6860-6870.
13. Sacco A, Roccaro A, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget 2010;1:578-582.
14. Signorovitch J, Swallow E, Kantor E, et al. Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison. Exp Hematol Oncol 2013;2:32.
15. Bellmunt J, Puente J, Garcia de MJ, et al. SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol 2014;16:1043-1050.
16. Agarwal R, Koenig K, Rohren E, et al. Combined antiangiogenic and mammalian target of rapamycin inhibitor targeted therapy in metaplastic breast cancer harboring a PIK3CA mutation. J Breast Cancer 2014;17:287-290.
17. Ma DJ, Galanis E, Anderson SK, et al. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol 2014;17:1261-1269.
18. Francis LK, Alsayed Y, Leleu X, et al. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res 2006;12:6826-6835.
19. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009;20:8023-8032.
20. Hoang B, Frost P, Shi Y, et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010;116:4560-4568.
21. Carracedo A, Baselga J, Pandolfi PP. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 2008;7:3805-3809.
22. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508.
23. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-1610.
24. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009;7:e38.
25. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: The second generation of inhibitors. Mol Cancer Ther 2011;10:395-403.
26. Dowling RJ, Topisirovic I, Fonseca BD, et al. Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochim Biophys Acta 2010;1804:433-439.
27. Cirstea D, Santo L, Hideshima T, et al. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. Mol Cancer Ther 2014;13:2489-2500.
28. Ghobrial IM, Weller E, Vij R, et al. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: A multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol 2011;12:263-272.
29. Yee AJ, Hari P, Marcheselli R, et al. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol 2014;166:401-409.
30. Ghobrial IM, Gertz M, LaPlant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1408-1414.
31. Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol 2014;89:237-242.
32. Gokmen-Polar Y, Liu Y, Toroni RA, et al. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Res Treat 2012;136:673-682.
33. Janes MR, Vu C, Mallya S, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia 2013;27:586-594.
34. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
35. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
36. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
37. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymph Myeloma 2006;6:380-383.
38. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009;27:120-126.
39. Infante JR, Tabernero J, Cervantes A, et al. A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC 1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies. Mol Cancer Ther 2013;12(11 Suppl):C252.
40. Burris H, Hart L, Kurkjian C, et al. A phase 1, open-label, dose-escalation study of oral administration of the investigational agent MLN0128 in combination with paclitaxel (P) in patients (pts) with advanced solid malignancies. Eur J Cancer 2012;48;186.
41. Rodon J, Dienstmann R, Serra V, et al. Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat Rev Clin Oncol 2013;10:143-153.
42. Shapiro GI, Rodon J, Bedell C, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2014;20:233-245.
43. Busaidy NL, Farooki A, Dowlati A, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 2012;30:2919-2928.
44. Sivendran S, Agarwal N, Gartrell B, et al. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev 2014;40:190-196.
45. Guenther A, Baumann P, Burger R, et al. Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. Haematologica 1904;100:541-547.
46. Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341-347.
47. Sahin I, Azab F, Mishima Y, et al. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. Am J Hematol 2014;89:1030-1036.